Intellipharmaceutics International Inc. in a Registered Direct Offering
Blank Rome represented Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, in a $3.1 million registered direct offering.